Common mole hair removal procedures include plucking, cosmetic waxing, electrolysis, threading and cauterization. Aging
Moles tend to appear during early childhood and during the first 30 years of life. They may change slowly, becoming raised, changing color or gradually fading. Most people have between 30 and 40 moles, but some have as many as 600.The number of moles a person has was found to have a correlation with telomere length. However, the relation between telomeres and aging remains uncertain. Complications
The American Academy of Dermatology says that the vast majority of moles are benign. Data on the chances of transformation from melanocytic nevus to melanoma is controversial, but it appears that about 10% of malignant melanomas have a precursor lesion, of which about 10% are melanocytic nevi. Therefore, it appears that malignant melanoma quite seldom (1% of cases) has a melanocytic nevus as a precursor. Cause
The cause is not clearly understood, but is thought to be caused by a defect in embryologic development. This is in the first twelve weeks of pregnancy. The defect is thought to cause a proliferation of melanocytes. This means melanocytes, the cells in the body in charge of normal skin color, are being produced at an extremely fast rate, thus causing the melanocytes to form in clusters instead of spread out, causing abnormal skin pigmentation in some areas of the body. Genetics
Genes can have an influence on a persons moles.
Cause
Selective IgA deficiency is inherited and has been associated with differences in chromosomes 18, 14 and 6. Selective IgA deficiency is often inherited, but has been associated with some congenital intrauterine infections. Pathophysiology
Pathogenesis of IgA Deficiency
‘In IgA-deficient patients, the common finding is a maturation defect in B cells to produce IgA’. ‘In IgA deficiency, B cells express IgA; however, they are of immature phenotype with the coexpression of IgM and IgD, and they cannot fully develop into IgA-secreting plasma cells’. There is an inherited inability to produce immunoglobulin A (IgA), a part of the bodys defenses against infection at the bodys surfaces (mainly the surfaces of the respiratory and digestive systems). As a result, bacteria at these locations are somewhat more able to cause disease.Types include:

Diagnosis
When suspected, the diagnosis can be confirmed by laboratory measurement of IgA level in the blood. SIgAD is an IgA level < 7 mg/dL with normal IgG and IgM levels (reference range 70–400 mg/dL for adults; children somewhat less). Treatment
The treatment consists of identification of co-morbid conditions, preventive measures to reduce the risk of infection, and prompt and effective treatment of infections. Infections in an IgA-deficient person are treated as usual (i.e., with antibiotics). There is no treatment for the underlying disorder. Use of IVIG as treatment
There is a historical popularity in using intravenous immunoglobulin (IVIG) to treat SIgAD, but the consensus is that there is no evidence that IVIG treats this condition.